Loading stock data…
Azenta, Inc. (AZTA)
$25.51+0.01 (+0.04%)
Market ClosedLast close Jun 29
Azenta, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Azenta, Inc. in the Healthcare sector is trading at $25.51 with a market capitalization of $1.1B. Wall Street consensus targets $26.20 (5 analysts), implying a +2.7% move over the next 12 months. The stock is currently 39% below its 52-week high of $41.73, remaining 10.5% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 71 is overbought against a weak tape. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 71 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $144.79M↓ | $148.64M↓ | $158.95M↑ | $143.94M↑ | $143.34M |
| Gross Profit | $62.03M↓ | $63.71M↓ | $67.96M↑ | $67.76M↑ | $62.78M |
| Operating Income | -$15.29M↓ | -$6.09M↓ | $1.78M↑ | $40,000↑ | -$14.61M |
| Net Income | -$160.80M↓ | -$15.43M↓ | $50.84M↑ | -$52.81M↓ | -$47.66M |
Peer Comparison
JNJUNHPFE
Fundamentals
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates thro...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.07B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.40
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-11.46%
Volume
Today's trading volume
484,432
Recent News
3 Reasons to Avoid AZTA and 1 Stock to Buy Instead
What a brutal six months it’s been for Azenta. The stock has dropped 30.3% and now trades at $24, rattling many shareholders. This was partly due to its softer quarterly results and might have investors contemplating their next move.
3 Cash-Heavy Stocks We Keep Off Our Radar
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.
3 Hyped Up Stocks We Find Risky
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.
3 Small-Cap Stocks with Open Questions
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
3 High-Flying Stocks Walking a Fine Line
“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated volatility during market downturns when expectations change.